InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.024 -0.009 (-27.27%)+
Announcement
Release
8 Jan 2026 9:30AM
Price at Release
$0.033
Full Release
download
Summary
Syntara Limited has announced the completion of patient recruitment for its Phase 2 trial of SNT-4728, aimed at treating isolated REM Sleep Behaviour Disorder (iRBD), which affects about 2% of individuals over 50 and poses a high risk of progression to neurodegenerative diseases. The trial, supported by Parkinson’s UK, is designed to evaluate SNT-4728's potential to reduce neuroinflammation, a key factor in the progression to Parkinson’s. It employs advanced brain imaging and includes an exploratory endpoint to assess improvement in iRBD symptoms. The study represents a significant milestone for Syntara, with top-line results anticipated in Q2 CY26, potentially influencing future directions in treating neurodegenerative conditions.
Key Points
  • Final patient recruited into Syntara’s Phase 2 trial of SNT-4728 for iRBD.
  • iRBD affects around 2% of individuals over 50 and may lead to neurodegenerative diseases.
  • Study tests SNT-4728's ability to reduce neuroinflammation linked to Parkinson’s.
  • Study supported by Parkinson’s UK through the Parkinson’s Virtual Biotech program.
  • Advanced brain imaging used to assess neuroinflammation reduction.
  • Exploratory endpoint to assess clinical symptom improvement of iRBD.
  • Recruitment completion marks a critical step for Syntara.
  • Study’s results could influence future neurodegenerative disorder treatments.
  • Potential to advance Syntara's clinical pipeline and development opportunities.
  • Top-line results expected in Q2 CY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.